Non-redundant immune checkpoints direct therapeutic resistance to chemoimmunotherapy in pancreatic ductal adenocarcinoma

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Research demonstrates that targeting myeloid cells may stratify immune checkpoint blockade efficacy, suggesting a new treatment strategy for PDA.

Combining anti-PD-1 therapy with chemotherapy and targeting myeloid cells improves T cell responses in pancreatic ductal adenocarcinoma.
Depletion of CSF1R+ myeloid cells triggers T cell infiltration but leads to limited tumor control, indicating treatment resistance factors.
High-dimensional analyses reveal multiple immune checkpoint upregulations in tumor environments, underscoring a complex immune landscape.
Combinatorial blockade of PD-1, LAG-3, and CTLA-4 is vital for effective T cell activation and significant tumor response in treatment.

Stone et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Research demonstrates that targeting myeloid cells may stratify immune checkpoint blockade efficacy, suggesting a new treatment strategy for PDA.